Onconetix Executes 1-for-10 Reverse Stock Split to Meet Nasdaq Listing Requirements
Event summary
- Onconetix's Board approved a 1-for-10 reverse stock split, effective May 21, 2026.
- The split reduces outstanding shares from ~11.4 million to ~1.14 million.
- Approval came from a special stockholder meeting on April 30, 2026.
- The move aims to maintain compliance with Nasdaq's $1 minimum bid price requirement.
- Fractional shares will be canceled, with cash compensation based on May 20, 2026 closing price.
The big picture
Onconetix's reverse stock split is a defensive maneuver to avoid Nasdaq delisting, common among small-cap biotechs facing prolonged low stock prices. The move reflects broader challenges in maintaining market compliance while advancing commercial-stage oncology products. The company's focus on Proclarix's U.S. launch via Labcorp underscores its pivot toward revenue-generating diagnostics amid financial restructuring.
What we're watching
- Liquidity Impact
- How the reduced share count affects trading liquidity and institutional investor participation.
- Market Perception
- Whether the split signals broader financial instability or a strategic pivot.
- Regulatory Compliance
- The pace at which Onconetix can stabilize its stock price to avoid further delisting risks.
Related topics